Market Place
Sourcing Support
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
21 Apr 2023 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio
20 Apr 2023 //
GLOBENEWSWIRE
Vallon Pharma Adjourns Special Meeting of Stockholders Until April 20, 2023
12 Apr 2023 //
GLOBENEWSWIRE
Vallon Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio
04 Apr 2023 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
24 Feb 2023 //
GLOBENEWSWIRE
Vallon and GRI Bio to Present at Investor 2023 Companies to Watch Event
11 Jan 2023 //
GLOBENEWSWIRE
Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement
13 Dec 2022 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results
28 Jul 2022 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
13 May 2022 //
GLOBENEWSWIRE
Vallon Pharma Reports Additional PK and PD Data from SEAL Study
12 May 2022 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Announces Issuance of Japanese Patent for ADAIR
11 May 2022 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Microcap biotech seeks a merger or new investment after PhIII flop — shares soar
22 Apr 2022 //
ENDPTS
Vallon Pharma to Participate at the 5th Annual Neuroscience Innovation Forum
23 Mar 2022 //
GLOBENEWSWIRE
Vallon`s abuse-resistant Adderall fails clinical trial; stocks plunge 70%
23 Mar 2022 //
BIZJOURNALS
Vallon Pharma Announces Topline Results of Pivotal SEAL Study for ADAIR in ADHD
21 Mar 2022 //
GLOBENEWSWIRE
Vallon Pharma Announces Issuance of U.S. Patent Covering ADAIR in COVID-19
28 Feb 2022 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Announces Appoints Meenu Karson to Board of Directors
28 Feb 2022 //
GLOBENEWSWIRE
Vallon Pharma Reports FY 2021 Financial Results, Provides Business Update
14 Feb 2022 //
GLOBENEWSWIRE
Vallon Pharma Presents New Data from Adult Stimulant Abuse Pattern Survey
18 Jan 2022 //
GLOBENEWSWIRE
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
04 Jan 2022 //
PRESS RELEASE
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit
23 Dec 2021 //
GLOBENEWSWIRE
Vallon Reports Q3 2021 Financial Results and Provides Corporate Update
12 Nov 2021 //
GLOBENEWSWIRE
Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel
10 Nov 2021 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern
01 Nov 2021 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate
12 Oct 2021 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
14 Sep 2021 //
GLOBENEWSWIRE
Vallon Pharmaceuticals Announces Issuance of New European Patent
13 Jul 2021 //
GLOBENEWSWIRE
Vallon Continues Advancement of Pivotal Study in Lead Development Program
13 Apr 2021 //
GLOBENEWSWIRE
Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation
08 Jan 2021 //
GLOBENEWSWIRE
Data from Vallon ADAIR Selected for Symposia Presentation at the Virtual 2021
08 Jan 2021 //
GLOBENEWSWIRE
Vallon Presents Positive Data from Proof-of-Concept Intranasal Abuse Study
09 Nov 2020 //
GLOBENEWSWIRE
AZ follows Amgen down KRAS/SHP2 combo path; Vallon files for $17 million IPO
27 Oct 2020 //
ENDPTS
